Connor, Clark & Lunn Investment Management (CC&L)’s Abeona Therapeutics ABEO Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio ABEO Stock Details ABEO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-10,297	Closed	-$404K	–	971
2020 Q4	$404K	Buy	10,297 +1,527	+17%	+$52K	﹤0.01%	751
2020 Q3	$224K	Sell	8,770 -2,664	-23%	-$168K	﹤0.01%	829
2020 Q2	$833K	Buy	11,434 +2,782	+32%	+$192K	0.01%	657
2020 Q1	$454K	Buy	8,652 +7,307	+543%	+$488K	﹤0.01%	717
2019 Q4	$110K	Buy	1,345 +404	+43%	+$28.5K	﹤0.01%	876
2019 Q3	$53K	Buy	+941	New	+$70.5K	﹤0.01%	933

Other funds holding ABEO

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s ABEO Position: Q1 2021 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of Abeona Therapeutics (ABEO) in Q1 2021, closing a stake of 10,297 shares — an estimated $404K sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in ABEO in Q3 2019 and held it in 6 quarters. The position peaked at $833K in Q2 2020. 75 funds tracked by Wall St. Rank hold ABEO as of Q1 2021.

Connor, Clark & Lunn Investment Management (CC&L) reported no remaining Abeona Therapeutics position as of Q1 2021 after selling out during the quarter.
Connor, Clark & Lunn Investment Management (CC&L) sold 10,297 Abeona Therapeutics shares in Q1 2021, an estimated $404K.
Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Abeona Therapeutics in Q3 2019 and held it in 6 quarters.
Connor, Clark & Lunn Investment Management (CC&L)'s Abeona Therapeutics position peaked at $833K in Q2 2020.
75 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q1 2021.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q1 2021, filed 13 May 2021.